Source: International Congress 2017 – Experimental PH
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Udjus (Oslo, Norway). A role for the inflammasome effector caspase-1 in hypoxia-induced pulmonary hypertension. 2373

Member's Comments

No comment yet.

Related content which might interest you: Statins worse pulmonary fibrosis through enhancing NLRP3 inflammasome activation Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012 Andrographolide inhibits the activation of NLRP3 inflammasome in patients with COPD Source: International Congress 2018 – Preclinical pharmacology: novel targets in airway inflammation, narrowing and neural control Year: 2018 TSC1/mTOR pathway promotes hypoxia-induced pulmonary hypertension in mice Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012 The activation of NLRP3 inflammasome pathway in COPD is limited in local airways Source: International Congress 2018 – Disease exacerbations from a molecular point of view Year: 2018 NLRP3 inflammasome conjugates with mitochondria in LPS-induced acute lung injury Source: Virtual Congress 2020 – Cellular stress in respiratory diseases Year: 2020 Tetracycline alleviates acute lung injury by inhibition of NLRP3 inflammasome Source: International Congress 2019 – ECMO, ECCO2R and other rescue therapies in acute respiratory failure Year: 2019 The inflammasome adaptor ASC mediates pulmonary artery remodelling Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 The dual role of apoptosis in pulmonary hypertension Source: Research Seminar 2005 - Pulmonary Circulation: Molecular Determinants of Pulmonary Vascular Remodelling Year: 2005 The NLRP3 inflammasome pathway is activated in sarcoidosis and involved in granuloma formation Source: Eur Respir J, 55 (3) 1900119; 10.1183/13993003.00119-2019 Year: 2020 Cigarette smoke extract inhibits the NLRP3 inflammasome in human macrophages and impairs cell metabolism via NLRP3-independent activation of Caspase-1 Source: International Congress 2019 – Effects of environmental exposures in lung pathology and the underlying mechanisms Year: 2019 Role of the inflammasome in idiopathic pulmonary fibrosis Source: International Congress 2017 – New insights into pathogenesis of lung disease  Year: 2017 NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung Source: Eur Respir J 2016; 47: 910-918 Year: 2016 Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension Source: Eur Respir J, 54 (6) 1900378; 10.1183/13993003.00378-2019 Year: 2019 In addition to mTOR and JAK/STAT, NLRP3 inflammasome is another key pathway activated in sarcoidosis Source: Eur Respir J, 55 (3) 2000149; 10.1183/13993003.00149-2020 Year: 2020 Defective p53-mediated pro-apoptotic pathway in idiopathic pulmonary fibrosis Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis Year: 2008 RAGE-dependent VCAM-1 expression in the pulmonary endothelium mediates IL-33 induced asthma pathogenesis Source: International Congress 2017 – Therapeutic approaches in lung disease Year: 2017 FIZZ1: a new pathway in silica-induced inflammatory mediators and pulmonary fibrosis Source: International Congress 2018 – Occupational and environmental lung diseases: mechanisms, biomarkers and causation Year: 2018 TRIM33 prevents pulmonary fibrosis by impairing TGF-ß1 signalling Source: Eur Respir J, 55 (6) 1901346; 10.1183/13993003.01346-2019 Year: 2020 Elevated expression of the NLRP3 inflammasome in neutrophilic asthma Source: Eur Respir J 2014; 43: 1067-1076 Year: 2014 Caspase-1 pathway in COPD Source: Annual Congress 2010 - COPD and asthma: models and human studies Year: 2010